Working... Menu

Sodium Nitrite to Treat Arterial Aging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02022670
Recruitment Status : Completed
First Posted : December 30, 2013
Results First Posted : June 17, 2015
Last Update Posted : July 15, 2015
TheraVasc Inc.
Information provided by (Responsible Party):
University of Colorado, Boulder

Brief Summary:
The proposed research will determine the effectiveness of nitrite, a naturally occurring compound in the body, for improving the health and function of arteries in middle-aged and older adults. The study also will provide insight into how sodium nitrite therapy improves artery health by determining the physiological mechanisms (biological reasons) involved. Overall, the proposed research will provide important new scientific evidence on the effectiveness of sodium nitrite for decreasing the risk of developing cardiovascular diseases with aging.

Condition or disease Intervention/treatment Phase
Vascular Aging Drug: Placebo Drug: Sodium Nitrite Phase 1 Phase 2

Detailed Description:
The improvement in blood vessel function and stiffness will be determined over a 10 week period. Subjects will be randomly assigned to either placebo (0 mg/day), low dose (80 mg/day) or high dose (160 mg/day) sodium nitrite. Main outcome measures will be performed at baseline and week 10.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Translation of Nitrite Therapy to Treat Arterial Aging in Humans
Study Start Date : October 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
Drug: Placebo
Sugar pill manufactured to mimic sodium nitrite capsules

Experimental: Sodium Nitrite 80 mg/d
80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Drug: Sodium Nitrite
80 mg/d or 160 mg/d
Other Name: TV1001

Experimental: Sodium Nitrite 160 mg/d
160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Drug: Sodium Nitrite
80 mg/d or 160 mg/d
Other Name: TV1001

Primary Outcome Measures :
  1. Baseline and Week 10 Flow-Mediated Dilation [ Time Frame: Baseline (Week 0), Week 10 ]
    Brachial artery flow mediated dilation (FMD) is assessed prior to entering the study. If subjects pass the inclusion requirements, FMD is analyzed at baseline and week 10. Flow-Mediated Dilation is calculated as the percent change in artery diameter in response to 5 minutes of cuff occlusion at Baseline and Week 10 timepoints; i.e. (Peak Diameter-Baseline Diameter)/Baseline Diameter x 100.

Secondary Outcome Measures :
  1. Baseline and Week 10 Plasma Nitrite Concentrations [ Time Frame: Baseline (Week 0), Week 10 ]
  2. Baseline and Week 10 Aortic Pulse Wave Velocity [ Time Frame: Baseline (Week 0), Week 10 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 50-79 years of age
  • Ability to provide informed consent
  • Score greater than 22 on the mini mental state exam
  • Blood pressure greater than 100/60 mmHg for past 3 months

Exclusion Criteria:

  • Are taking any of the following medications/drugs: hormone replacement therapy, anti-hypertensives, nitrates, nervous system depressants, allopurinol, phosphodiesterase-5 inhibitors, blood thinners
  • Are currently sick/have chronic clinical diseases such as kidney disease, diabetes, or unstable cardiovascular disease
  • Are hypersensitive to nitrates or nitrites
  • Have glucose-6-phosphate dehydrogenase deficiency
  • Have blood methemoglobin greater than 2%
  • Have a BMI greater than 40 kg/m^2
  • Have a baseline FMD of greater than 6%
  • Have not been post-menopausal for at least 1 year
  • Perform regular vigorous aerobic/endurance exercise

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02022670

Layout table for location information
United States, Colorado
Clinical Translational Research Center
Boulder, Colorado, United States, 80309
Sponsors and Collaborators
University of Colorado, Boulder
TheraVasc Inc.
Layout table for investigator information
Principal Investigator: Douglas R Seals, Ph.D. University of Colorado, Boulder
Study Director: Allison E DeVan, Ph.D. University of Colorado, Boulder

Additional Information:
Layout table for additonal information
Responsible Party: University of Colorado, Boulder Identifier: NCT02022670     History of Changes
Other Study ID Numbers: R21HL107105 ( U.S. NIH Grant/Contract )
First Posted: December 30, 2013    Key Record Dates
Results First Posted: June 17, 2015
Last Update Posted: July 15, 2015
Last Verified: June 2015

Keywords provided by University of Colorado, Boulder:
endothelial function
arterial stiffness
flow-mediated dilation
pulse wave velocity
sodium nitrite
vascular diseases